Company: ABUS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001447028-25-000126
Chunk: 20

Company: Arbutus Biopharma Corp
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands of U.S. Dollars, except share amounts)

September 30, 2025December 31, 2024AssetsCurrent assets:Cash and cash equivalents$22,408 $36,330 Investments in marketable securities, current71,294 86,293 Accounts receivable905 2,409 Prepaid expenses and other current assets2,835 2,284 Total current assets97,442 127,316 Property and equipment, net of accumulated depreciation and impairment of $13,347 (December 31, 2024: $12,996) 137 3,309 Right of use asset— 1,048 Other non-current assets131 34 Total assets$97,710 $131,707 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable and accrued liabilities$4,653 $7,564 Deferred license revenue, current— 7,571 Lease liability, current531 483 Total current liabilities5,184 15,618 Liability related to sale of future royalties3,684 4,829 Deferred license revenue, non-current— 2,863 Contingent consideration11,052 10,225 Lease liability, non-current391 806 Total liabilities20,311 34,341 Stockholders’ equity  Common sharesAuthorized: unlimited number without par valueIssued and outstanding: 191,953,665(December 31, 2024: 189,963,492)1,418,560 1,410,025 Additional paid-in capital83,285 82,048 Deficit(1,376,317)(1,346,572)Accumulated other comprehensive loss(48,129)(48,135)Total stockholders’ equity77,399 97,366 Total liabilities and stockholders’ equity$97,710 $131,707 

See accompanying notes to the condensed consolidated financial statements.

1

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands of U.S. Dollars, except share and per share amounts)

Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Revenue